ULB and Hôpital de Marche (Vivalia)
" Three axes to improve SARS-CoV-2 infection detection. 1. Development of RNA positive controls for real-time PCR allowing to give the SARS-CoV-2 RNA results in viral load quantification. Development of samples carrying eukaryote mRNA and recombinant RNA positive controls allowing to give after reverse transcription and real-time PCR the results in viral load/copy number. Method: The amplified region of the SARS-CoV-2 E gene was cloned in a E. coli expression vector allowing recombinant mRNA production after IPTG induction. Positive control samples are prepared by adding a known copy numbers of SARS-CoV-2 RNA to human eukaryote RNA, in order to have standard positive controls during the diagnosis method. 2. Development of a new SARS-CoV-2 diagnosis assay allowing point-of-care testing using the SHERLOCK diagnostics system. 3. Production of recombinant proteins allowing for anti-SARS-CoV-2 immunoglobulin detection by ELISA."
Contact: Véronique Fontaine, This email address is being protected from spambots. You need JavaScript enabled to view it.